What if the drug that could effectively treat amyotrophic lateral sclerosis, the paralyzing neurological disease that skyrocketed into the public consciousness thanks to the ice bucket challenge, already exists?
That s the question confronting Jackie Hunter, CEO of BenevolentBio.
Hunter runs the biomedical arm of the artificial intelligence firm BenevolentAI, applying machine learning to vast databases of medical research to rapidly scan and organize the data.
It seems unlikely that rehashing scientific research could lead to new discoveries, but new studies on life sciences are published every 30 seconds, so valuable research is often missed.
Hunter told TechCrunch today at Disrupt London that BenevolentBio s AI has already succeeded.
BenevolentBio s AI scanned for studies that might hold secrets about ALS treatment.